ABO DIAG has been acquired by DIAGAST
The private shareholders and investment funds Succes Eur. and Aqui Invest, based in France, have sold ABO DIAG to DIAGAST for US$6.5 million.
ABO DIAG was founded in 2008 by its CEO, Najim Chaibi. Located in the technopolis of Montesquieu, the company is based on the research and development of diagnostic devices dedicated to blood transfusion and more widely to immuno-haematology. ABO DIAG is a pioneer in the field of research of new solutions for haematological diagnosis. The company's patent protected technology is based on immunological detection in vertical flow with colored dots. This innovation provides higher sensibility and higher safety in diagnosis, thanks to a simple user procedure and with standardized results. ABO DIAG was awarded the First Prize of Innovation at JIB 2012 (Innovation of the year in Biology).
DIAGAST is the worldwide leader in the marketing and development of reagents and instrumentation systems that aim to ensure donor and patient compatibility during blood transfusions. Over the last 30 years, the company has developed unparalleled expertise and know-how in the transfusion sector.
Oaklins' team in France advised the seller in this transaction.
Talk to the deal team
Related deals
Bolster Investment Partners has acquired a majority stake in Eternal Sun
Bolster Investment Partners, a Netherlands-based investment firm, has acquired a majority stake in Eternal Sun, a global technology leader in advanced solar panel testing equipment, from ABN AMRO Sustainable Impact Fund, a private impact fund based in the Netherlands, and Vermec, a Belgium-based investment firm.
Learn moreCerbios-Pharma has been acquired by HAS Healthcare
Cerbios-Pharma S.A. has been acquired by HAS Healthcare Advanced Synthesis S.A., forming a leading global contract development and manufacturing organization (CDMO) group. This transaction results in a seamless integration of complementary capabilities, combining extensive expertise in production, chemical and biological sciences and technical excellence, all designed to meet the evolving demands of the global pharmaceutical sector.
Learn moreiwell raises US$31 million to deploy its leading European smart battery storage solutions into new markets
iwell, a developer of smart energy management (EMS) and battery storage systems (BESS), has successfully closed a US$31 million (€27 million) funding round. The round was led by Meridiam, with Invest-NL and Rabobank participating, alongside existing investors.
Learn more